Semaglutide
What is Semaglutide?
Semaglutide is a GLP-1 receptor agonist that mimics the action of the human glucagon-like peptide-1 (GLP-1). It increases insulin secretion, decreases glucagon secretion, and slows gastric emptying.
Mechanism of Action
Acts on GLP-1 receptors in the brain to regulate appetite and food intake. It also enhances glucose-dependent insulin secretion from the pancreas.
Benefits
- Significant weight loss
- Improved blood sugar control
- Reduced appetite and cravings
- Cardiovascular benefits
- Potential neuroprotective effects
Typical Dosage
- 0.25mg weekly, titrating up to 2.4mg weekly
Side Effects
- Nausea
- Vomiting
- Diarrhea
- Constipation
- Fatigue
Dosage Protocol
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist with a prolonged half-life of approximately 7 days. This educational protocol presents a gradual weekly titration from 0.25 mg up to a maintenance dose of 2.4 mg over 16+ weeks. Weekly dose range: 250–2400 mcg (0.25–2.4 mg) once weekly.
Reconstitution
Dosing Schedule
Standard Protocol
- •Frequency: Inject once weekly subcutaneously
- •Timing: Administer on the same day each week
- •Titration: Gradual increase from 0.25mg to 2.4mg over 16+ weeks
Negative Interactions
- Alcohol
- High-fat meals
- Other GLP-1 medications
This guide is for educational purposes only. Always consult with a qualified healthcare professional.